Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL ALLOGRAFT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL ALLOGRAFT MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 SALES VOLUME DATA
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL ALLOGRAFT MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER'S FIVE FORCES MODEL
6 INDUSTRY INSIGHTS
6.1 MICRO AND MACRO ECONOMIC FACTORS
6.2 PENETRATION AND GROWTH PROSPECT MAPPING
6.3 KEY PRICING STRATEGIES
6.4 INTERVIEWS WITH SPECIALIST
6.5 ANALYSIS AND RECOMMENDATIONS
7 INTELLECTUAL PROPERTY (IP) PORTFOLIO
7.1 PATENT QUALITY AND STRENGTH
7.2 PATENT FAMILIES
7.3 LICENSING AND COLLABORATIONS
7.4 COMPETITIVE LANDSCAPE
7.5 IP STRATEGY AND MANAGEMENT
7.6 OTHER
8 COST ANALYSIS BREAKDOWN
9 TECHNOLOGY ROADMAP
10 INNOVATION TRACKER AND STRATEGIC ANALYSIS
10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
10.1.1 JOINT VENTURES
10.1.2 MERGERS AND ACQUISITIONS
10.1.3 LICENSING AND PARTNERSHIP
10.1.4 TECHNOLOGY COLLABORATIONS
10.1.5 STRATEGIC DIVESTMENTS
10.2 NUMBER OF PRODUCTS IN DEVELOPMENT
10.3 STAGE OF DEVELOPMENT
10.4 TIMELINES AND MILESTONES
10.5 INNOVATION STRATEGIES AND METHODOLOGIES
10.6 RISK ASSESSMENT AND MITIGATION
10.7 FUTURE OUTLOOK
11 REGULATORY COMPLIANCE
11.1 REGULATORY AUTHORITIES
11.2 REGULATORY CLASSIFICATIONS
11.2.1 CLASS I
11.2.2 CLASS II
11.2.3 CLASS III
11.3 REGULATORY SUBMISSIONS
11.4 INTERNATIONAL HARMONIZATION
11.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
11.6 REGULATORY CHALLENGES AND STRATEGIES
12 REIMBURSEMENT FRAMEWORK
13 OPPUTUNITY MAP ANALYSIS
14 INSTALLED BASE DATA
15 VALUE CHAIN ANALYSIS
16 HEALTHCARE ECONOMY
16.1 HEALTHCARE EXPENDITURE
16.2 CAPITAL EXPENDITURE
16.3 CAPEX TRENDS
16.4 CAPEX ALLOCATION
16.5 FUNDING SOURCES
16.6 INDUSTRY BENCHMARKS
16.7 GDP RATION IN OVERALL GDP
16.8 HEALTHCARE SYSTEM STRUCTURE
16.9 GOVERNMENT POLICIES
16.1 ECONOMIC DEVELOPMENT
17 GLOBAL ALLOGRAFT MARKET, BY TYPE
17.1 OVERVIEW
17.2 BONE ALLOGRAFT
17.2.1 BY TYPE
17.2.1.1. CORTICAL BONE ALLOGRAFTS
17.2.1.2. DEMINERALIZED BONE MATRIX
17.2.1.3. OSTEOCHONDRAL AND CORTICAL ALLOGRAFTS
17.2.1.4. MORSELIZED AND CANCELLOUS BONE ALLOGRAFTS
17.2.1.5. CANCELLOUS/CORTICOCANCELLOUS ALLOGRAFTS
17.2.2 BY FORM
17.2.2.1. CHIPS AND CUBES
17.2.2.2. BONE DOWELS
17.2.2.3. STRUTS
17.2.2.4. HEADS
17.2.2.5. WEDGES
17.2.2.6. SHAFTS
17.2.2.7. SPACERS
17.2.2.8. OTHERS
17.2.3 BY APPLICATION
17.2.3.1. DENTISTRY
17.2.3.2. ORTHOPAEDIC
17.2.3.3. SPINAL
17.2.3.4. TRAUMA
17.2.3.5. PLASTIC SURGERY
17.2.3.6. CARDIOLOGY
17.2.3.7. OTHERS
17.3 SOFT TISSUE ALLOGRAFT
17.3.1 BY TYPE
17.3.1.1. CARTILAGE ALLOGRAFT
17.3.1.1.1. COSTAL CARTILAGE
17.3.1.1.2. OSTEOCHONDRAL ALLOGRAFT PLUGS
17.3.1.1.3. OSTEOCHONDRAL ALLOGRAFT
17.3.1.2. TENDON ALLOGRAFT
17.3.1.2.1. NON-BONE TENDON ALLOGRAFT
17.3.1.2.2. BONE & BTB TENDON ALLOGRAFT
17.3.1.3. MENISCUS ALLOGRAFT
17.3.1.3.1. MEDIAL ALLOGRAFT
17.3.1.3.2. LATERAL ALLOGRAFT
17.3.1.4. DENTAL ALLOGRAFT
17.3.1.5. COLLAGEN ALLOGRAFT
17.3.1.6. AMNIOTIC ALLOGRAFT
17.3.2 BY APPLICATION
17.3.2.1. DENTISTRY
17.3.2.2. ORTHOPAEDIC
17.3.2.3. SPINAL
17.3.2.4. TRAUMA
17.3.2.5. PLASTIC SURGERY
17.3.2.6. CARDIOLOGY
17.3.2.7. OTHERS
17.4 MACHINED ALLOGRAFT
17.5 OTHERS
18 GLOBAL ALLOGRAFT MARKET, BY APPLICATION
18.1 OVERVIEW
18.2 DENTISTRY
18.2.1 BONE ALLOGRAFT
18.2.2 SOFT TISSUE ALLOGRAFT
18.2.3 MACHINED ALLOGRAFT
18.3 ORTHOPAEDIC
18.3.1 BONE ALLOGRAFT
18.3.2 SOFT TISSUE ALLOGRAFT
18.3.3 MACHINED ALLOGRAFT
18.4 SPINAL
18.4.1 BONE ALLOGRAFT
18.4.2 SOFT TISSUE ALLOGRAFT
18.4.3 MACHINED ALLOGRAFT
18.5 TRAUMA
18.5.1 BONE ALLOGRAFT
18.5.2 SOFT TISSUE ALLOGRAFT
18.5.3 MACHINED ALLOGRAFT
18.6 PLASTIC SURGERY
18.6.1 BONE ALLOGRAFT
18.6.2 SOFT TISSUE ALLOGRAFT
18.6.3 MACHINED ALLOGRAFT
18.7 CARDIOLOGY
18.8 OTHER APPLICATIONS
19 GLOBAL ALLOGRAFT MARKET, BY DEMOGRAPHY
19.1 OVERVIEW
19.2 PEDIATRIC
19.3 ADULT
19.4 GERIARTIC
20 GLOBAL ALLOGRAFT MARKET, BY PRICE RANGE
20.1 OVERVIEW
20.2 PREMIUM
20.3 LOW COST
21 GLOBAL ALLOGRAFT MARKET, BY TECHNOLOGY
21.1 OVERVIEW
21.2 MINIMALLY PROCESSED
21.3 HIGHLY PROCESSED
22 GLOBAL ALLOGRAFT MARKET, BY END USER
22.1 OVERVIEW
22.2 HOSPITALS
22.2.1 BY TYPE
22.2.1.1. PUBLIC
22.2.1.2. PRIVATE
22.2.2 BY TIER
22.2.2.1. TIER 1
22.2.2.2. TIER 2
22.2.2.3. TIER 3
22.3 TRAUMA CENTERS
22.4 CLINICS
22.5 AMBULATORY SURGICAL CENTERS
22.6 ACADEMIC AND RESEARCH INSTITUTES
22.7 OTHER
23 GLOBAL ALLOGRAFT MARKET, BY DISTRIBUTION CHANNEL
23.1 OVERVIEW
23.2 DIRECT TENDER
23.3 RETAIL SALES
23.4 OTHERS
24 GLOBAL ALLOGRAFT MARKET, COMPANY LANDSCAPE
24.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
24.2 COMPANY SHARE ANALYSIS: EUROPE
24.3 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
24.4 MERGERS & ACQUISITIONS
24.5 NEW PRODUCT DEVELOPMENT & APPROVALS
24.6 EXPANSIONS
24.7 REGULATORY CHANGES
24.8 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
25 GLOBAL ALLOGRAFT MARKET, SWOT AND DBMR ANALYSIS
26 GLOBAL ALLOGRAFT MARKET, BY REGION
GLOBAL ALLOGRAFT MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
26.1 NORTH AMERICA
26.1.1 U.S.
26.1.2 CANADA
26.1.3 MEXICO
26.2 EUROPE
26.2.1 GERMANY
26.2.2 FRANCE
26.2.3 U.K.
26.2.4 HUNGARY
26.2.5 LITHUANIA
26.2.6 AUSTRIA
26.2.7 IRELAND
26.2.8 NORWAY
26.2.9 POLAND
26.2.10 ITALY
26.2.11 SPAIN
26.2.12 RUSSIA
26.2.13 TURKEY
26.2.14 NETHERLANDS
26.2.15 SWITZERLAND
26.2.16 REST OF EUROPE
26.3 ASIA-PACIFIC
26.3.1 JAPAN
26.3.2 CHINA
26.3.3 SOUTH KOREA
26.3.4 INDIA
26.3.5 AUSTRALIA
26.3.6 SINGAPORE
26.3.7 THAILAND
26.3.8 MALAYSIA
26.3.9 INDONESIA
26.3.10 PHILIPPINES
26.3.11 VIETNAM
26.3.12 REST OF ASIA-PACIFIC
26.4 SOUTH AMERICA
26.4.1 BRAZIL
26.4.2 ARGENTINA
26.4.3 PERU
26.4.4 COLOMBIA
26.4.5 VENEZUELA
26.4.6 REST OF SOUTH AMERICA
26.5 MIDDLE EAST AND AFRICA
26.5.1 SOUTH AFRICA
26.5.2 SAUDI ARABIA
26.5.3 UAE
26.5.4 EGYPT
26.5.5 KUWAIT
26.5.6 ISRAEL
26.5.7 REST OF MIDDLE EAST AND AFRICA
26.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
27 GLOBAL ALLOGRAFT MARKET, COMPANY PROFILE
27.1 ZIMMER BIOMET
27.1.1 COMPANY OVERVIEW
27.1.2 REVENUE ANALYSIS
27.1.3 GEOGRAPHIC PRESENCE
27.1.4 PRODUCT PORTFOLIO
27.1.5 RECENT DEVELOPMENTS
27.2 ABBVIE.
27.2.1 COMPANY OVERVIEW
27.2.2 REVENUE ANALYSIS
27.2.3 GEOGRAPHIC PRESENCE
27.2.4 PRODUCT PORTFOLIO
27.2.5 RECENT DEVELOPMENTS
27.3 CONMED CORPORATION
27.3.1 COMPANY OVERVIEW
27.3.2 REVENUE ANALYSIS
27.3.3 GEOGRAPHIC PRESENCE
27.3.4 PRODUCT PORTFOLIO
27.3.5 RECENT DEVELOPMENTS
27.4 XTANT MEDICAL
27.4.1 COMPANY OVERVIEW
27.4.2 REVENUE ANALYSIS
27.4.3 GEOGRAPHIC PRESENCE
27.4.4 PRODUCT PORTFOLIO
27.4.5 RECENT DEVELOPMENTS
27.5 LEMAITRE VASCULAR, INC.
27.5.1 COMPANY OVERVIEW
27.5.2 REVENUE ANALYSIS
27.5.3 GEOGRAPHIC PRESENCE
27.5.4 PRODUCT PORTFOLIO
27.5.5 RECENT DEVELOPMENTS
27.6 CELULARITY INC.
27.6.1 COMPANY OVERVIEW
27.6.2 REVENUE ANALYSIS
27.6.3 GEOGRAPHIC PRESENCE
27.6.4 PRODUCT PORTFOLIO
27.6.5 RECENT DEVELOPMENTS
27.7 LEADER BIOMEDICAL
27.7.1 COMPANY OVERVIEW
27.7.2 REVENUE ANALYSIS
27.7.3 GEOGRAPHIC PRESENCE
27.7.4 PRODUCT PORTFOLIO
27.7.5 RECENT DEVELOPMENTS
27.8 ARTHREX, INC.
27.8.1 COMPANY OVERVIEW
27.8.2 REVENUE ANALYSIS
27.8.3 GEOGRAPHIC PRESENCE
27.8.4 PRODUCT PORTFOLIO
27.8.5 RECENT DEVELOPMENTS
27.9 BONE BANK ALLOGRAFTS
27.9.1 COMPANY OVERVIEW
27.9.2 REVENUE ANALYSIS
27.9.3 GEOGRAPHIC PRESENCE
27.9.4 PRODUCT PORTFOLIO
27.9.5 RECENT DEVELOPMENTS
27.1 INTEGRA LIFESCIENCES
27.10.1 COMPANY OVERVIEW
27.10.2 REVENUE ANALYSIS
27.10.3 GEOGRAPHIC PRESENCE
27.10.4 PRODUCT PORTFOLIO
27.10.5 RECENT DEVELOPMENTS
27.11 TISSUE REGENIX
27.11.1 COMPANY OVERVIEW
27.11.2 REVENUE ANALYSIS
27.11.3 GEOGRAPHIC PRESENCE
27.11.4 PRODUCT PORTFOLIO
27.11.5 RECENT DEVELOPMENTS
27.12 DEPUY SYNTHES
27.12.1 COMPANY OVERVIEW
27.12.2 REVENUE ANALYSIS
27.12.3 GEOGRAPHIC PRESENCE
27.12.4 PRODUCT PORTFOLIO
27.12.5 RECENT DEVELOPMENTS
27.13 ORTHOFIX HOLDINGS, INC.
27.13.1 COMPANY OVERVIEW
27.13.2 REVENUE ANALYSIS
27.13.3 GEOGRAPHIC PRESENCE
27.13.4 PRODUCT PORTFOLIO
27.13.5 RECENT DEVELOPMENTS
27.14 SMITH & NEPHEW
27.14.1 COMPANY OVERVIEW
27.14.2 REVENUE ANALYSIS
27.14.3 GEOGRAPHIC PRESENCE
27.14.4 PRODUCT PORTFOLIO
27.14.5 RECENT DEVELOPMENTS
27.15 STRYKER
27.15.1 COMPANY OVERVIEW
27.15.2 REVENUE ANALYSIS
27.15.3 GEOGRAPHIC PRESENCE
27.15.4 PRODUCT PORTFOLIO
27.15.5 RECENT DEVELOPMENTS
27.16 ENOVIS
27.16.1 COMPANY OVERVIEW
27.16.2 REVENUE ANALYSIS
27.16.3 GEOGRAPHIC PRESENCE
27.16.4 PRODUCT PORTFOLIO
27.16.5 RECENT DEVELOPMENTS
27.17 RTI SURGICAL
27.17.1 COMPANY OVERVIEW
27.17.2 REVENUE ANALYSIS
27.17.3 GEOGRAPHIC PRESENCE
27.17.4 PRODUCT PORTFOLIO
27.17.5 RECENT DEVELOPMENTS
27.18 AZIYO BIOLOGICS
27.18.1 COMPANY OVERVIEW
27.18.2 REVENUE ANALYSIS
27.18.3 GEOGRAPHIC PRESENCE
27.18.4 PRODUCT PORTFOLIO
27.18.5 RECENT DEVELOPMENTS
27.19 CAMLOG BIOTECHNOLOGIES GMBH
27.19.1 COMPANY OVERVIEW
27.19.2 REVENUE ANALYSIS
27.19.3 GEOGRAPHIC PRESENCE
27.19.4 PRODUCT PORTFOLIO
27.19.5 RECENT DEVELOPMENTS
27.2 ORGANOGENESIS INC.
27.20.1 COMPANY OVERVIEW
27.20.2 REVENUE ANALYSIS
27.20.3 GEOGRAPHIC PRESENCE
27.20.4 PRODUCT PORTFOLIO
27.20.5 RECENT DEVELOPMENTS
27.21 SPINAL ELEMENTS, INC.
27.21.1 COMPANY OVERVIEW
27.21.2 REVENUE ANALYSIS
27.21.3 GEOGRAPHIC PRESENCE
27.21.4 PRODUCT PORTFOLIO
27.21.5 RECENT DEVELOPMENTS
27.22 GLOBUS MEDICAL INC.
27.22.1 COMPANY OVERVIEW
27.22.2 REVENUE ANALYSIS
27.22.3 GEOGRAPHIC PRESENCE
27.22.4 PRODUCT PORTFOLIO
27.22.5 RECENT DEVELOPMENTS
27.23 NVISION BIOMEDICAL TECHNOLOGIES, INC.
27.23.1 COMPANY OVERVIEW
27.23.2 REVENUE ANALYSIS
27.23.3 GEOGRAPHIC PRESENCE
27.23.4 PRODUCT PORTFOLIO
27.23.5 RECENT DEVELOPMENTS
27.24 VIVEX BIOLOGICS, INC.
27.24.1 COMPANY OVERVIEW
27.24.2 REVENUE ANALYSIS
27.24.3 GEOGRAPHIC PRESENCE
27.24.4 PRODUCT PORTFOLIO
27.24.5 RECENT DEVELOPMENTS
27.25 BIOVENTUS
27.25.1 COMPANY OVERVIEW
27.25.2 REVENUE ANALYSIS
27.25.3 GEOGRAPHIC PRESENCE
27.25.4 PRODUCT PORTFOLIO
27.25.5 RECENT DEVELOPMENTS
27.26 B. BRAUN SE
27.26.1 COMPANY OVERVIEW
27.26.2 REVENUE ANALYSIS
27.26.3 GEOGRAPHIC PRESENCE
27.26.4 PRODUCT PORTFOLIO
27.26.5 RECENT DEVELOPMENTS
27.27 ALLIQUA BIOMEDICAL, INC.
27.27.1 COMPANY OVERVIEW
27.27.2 REVENUE ANALYSIS
27.27.3 GEOGRAPHIC PRESENCE
27.27.4 PRODUCT PORTFOLIO
27.27.5 RECENT DEVELOPMENTS
27.28 BAXTER
27.28.1 COMPANY OVERVIEW
27.28.2 REVENUE ANALYSIS
27.28.3 GEOGRAPHIC PRESENCE
27.28.4 PRODUCT PORTFOLIO
27.28.5 RECENT DEVELOPMENTS
28 RELATED REPORTS
29 CONCLUSION
30 QUESTIONNAIRE
31 ABOUT DATA BRIDGE MARKET RESEARCH
